Tonix Pharmaceuticals Holding Corp.

NASDAQ:TNXP

Biotechnology

Healthcare
$2.82 -1.97%

-$0.24 today

Market cap
$54.80M
Beta
1.68
P/E (TTM)
-1.1
EPS (TTM)
-$10.75
52W Low $10.03High $69.97

Volume 1.04M

Average 0.49M

TNXP Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Tonix Pharmaceuticals Holding Corp.NASDAQ: TNXP

Net Receivables · Q1 FY2026 · quarter ended Mar 2026

Net receivables rises 82.7% from a year ago

Net receivables stood at $8.82M at the end of Q1 FY2026, up 82.7% from a year earlier and down 9.6% from the prior quarter. Over 3 fiscal years it compounded at +6.6% a year.

Context

  • Net receivables amounted to 3.4% of total assets at the end of Q1 FY2026, up 0.9 pp from a year earlier.
  • Net receivables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net receivables keeps rising in the next quarterly balance sheet after a +82.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$8.82M-9.6% QoQ
Last fiscal yearDec 2025
$9.76M+23.4% YoY
Year agoMar 2025
$4.83M+82.7% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+82.7%——
1 year+23.4%——
3-year CAGR+6.6%——
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
9.76M USD
Year-over-year change
+23.4%
4-year CAGR
+6.0%

Net Receivables vs competitors

How TNXP compares with its peers on the latest reported figures

  • Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +82.7% is the 3rd highest of 7, against a peer median of -26.3%.
  • Net receivables amounts to 3.4% of total assets for TNXP, versus a peer median of 0.4%.
TNXP Competitors
Net Receivables for TNXP and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
TNXPTonix Pharmaceuticals Holding Corp.Mar 2026$8.82M USD+82.7%+6.6%3.4%
IPHAInnate Pharma S.A.Dec 2025€7.61M EUR+363.2%+34.3%12.1%
MISTMilestone Pharmaceuticals Inc.Mar 2026$5M USD+131.4%+42.5%2.6%
NKTXNkarta, Inc.Mar 2026$1.7M USD-29.2%+15.4%0.5%
FATEFate Therapeutics, Inc.Mar 2026$704K USD-70.7%-71.2%0.2%
FBRXForte Biosciences, Inc.Mar 2026$655K USD——1.0%
ELDNEledon Pharmaceuticals, Inc.Mar 2026$583K USD-23.4%—0.4%
MCRBSeres Therapeutics, Inc.Mar 2026$233K USD-94.7%—0.2%
AVTXAvalo Therapeutics, Inc.Mar 2026$0 USD——0.0%
ELTXElicio Therapeutics, Inc.Mar 2026$0 USD——0.0%
Peer median (excluding TNXP) —-26.3%+24.9%0.4%

Competitors are the stored peer set for TNXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents178.66M120.23M24.95M98.78M207.64M
Short-term Investments00000
Net Receivables7.73M8.04M4.59M7.9M9.76M
Inventory0014.15M8.41M6.01M
Other Current Assets1.18M1.23M2.43M1.46M5.47M
Total Current Assets189.05M130.78M47.77M119M228.88M
Property, Plant & Equipment (Net)51.47M94.53M94.85M42.82M46M
Goodwill00965K00
Intangible Assets120K120K9.74M120K120K
Long-term Investments240K00904K2.18M
Tax Assets(240K)0000
Other Non-current Assets259K264K1.13M47K0
Total Non-current Assets51.85M94.91M106.69M43.89M48.3M
Total Assets240.9M225.69M154.46M162.89M277.17M
Account Payables13.28M8.07M3.78M4.55M8.11M
Short-term Debt002.35M00
Tax Payables00000
Deferred Revenue2.83M3.27M2.98M1.82M3.43M
Other Current Liabilities2.25M3.65M5.14M7.32M11.26M
Total Current Liabilities21.72M18.18M18.88M18.31M30.84M
Long-term Debt006.56M4.67M0
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities0022.86M00
Total Non-current Liabilities467K328K30.05M5.03M1.18M
Total Liabilities22.18M18.51M48.93M23.33M32.02M
Common Stock496K12K59K4K13K
Retained Earnings(359.82M)(470.04M)(600.66M)(730.69M)(854.72M)
Accumulated OCI(92K)(167K)(232K)(255K)(289K)
Other Stockholders Equity480K0000
Minority Interest00000
Total Equity218.72M207.18M105.53M139.56M245.15M
Total Debt956K760K9.81M5.3M1.31M
Net Debt(177.7M)(119.47M)(15.14M)(93.48M)(206.33M)

Tonix Pharmaceuticals Holding Corp.

NASDAQ:TNXP

Intrinsic Alpha fair value

Locked

Current Price

$2.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.